Absolute Values of Reticulocyte Count at Baseline (Day 1), Week 1, 2, 3, 4, and 6;Model-Adjusted Maximum Hgb Changes Over 4 Weeks;Number of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb;Percentage of Participants Achieving an Increase of 0.5, 1.0, 1.5 and 2.0 g/dL in Hgb;Number of Participants Who Reached Hgb Stopping Criteria;Change From Baseline in Hepcidin at Week 2 and Week 4;Change From Baseline in Ferritin at Week 2 and Week 4;Change From Baseline in Transferrin at Week 2 and Week 4;Change From Baseline in Transferrin Saturation at Week 2 and Week 4;Change From Baseline in Total Iron Binding Capacity at Week 2 and Week 4;Change From Baseline in Total Iron at Week 2 and Week 4;Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 2 and Week 4;Change From Baseline in Hematocrit and Reticulocytes Over 4 Weeks;Change From Baseline in Erythropoietin at Week 2 and Week 4;Change From Baseline in Red Blood Cells Count Over 4 Weeks;Change From Baseline in Vascular Endothelial Growth Factor (VEGF) at Week 2 and Week 4;Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelet Count, WBC Count (Absolute) at Week 1, 2, 3, 4, and 6;Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs);Number of Participants Discontinuing the Study Treatment Due to AEs;Absolute Values of Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) at Baseline (Day 1), Week 2, 4, and 6;Absolute Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Baseline (Day 1), Week 2, 4, and 6;Absolute Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Baseline (Day 1), Week 2, 4, and 6;Absolute Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Baseline (Day 1), Week 2, 4, and 6;Absolute Values of Urine Total Protein/Creatinine Ratio at Baseline (Day 1), Week 2, 4, and 6;Change From Baseline Values of ALT, ALP, AST, CK at Week 2, 4, and 6;Change From Baseline Values of Albumin, Apolipoprotein A1, Apolipoprotein Total, Total Protein at Week 2, 4, and 6;Change From Baseline Values of Calcium, Chloride, Cholesterol, Glucose, Inorganic Phosphorus, Potassium, Sodium at Week 2, 4, and 6;Change From Baseline Values of Creatinine, Direct Bilirubin, Indirect Bilirubin, Total Bilirubin at Week 2, 4, and 6;Change From Baseline Values of Urine Total Protein/Creatinine Ratio at Week 2, 4, and 6;Absolute Values of Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, WBC Count (Absolute) at Baseline, Week 1, 2, 3, 4, and 6;Absolute Values of Mean Corpuscle Volume at Baseline, Week 1, 2, 3, 4 and 6;Absolute Values of Mean Corpuscle Hgb Concentration at Baseline (Day 1), Week 1, 2, 3, 4, and 6;Change From Baseline in Mean Corpuscle Volume at Week 1, 2, 3, 4, and 6;Change From Baseline in Mean Corpuscle Hgb Concentration at Week 1, 2, 3, 4, and 6;Absolute Values of Systolic Blood Pressure and Diastolic Blood Pressure Baseline, Week 1, Week 2, Week 3, Week 4 and Week 6;Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure at Week 1, 2, 3, 4, and 6;Absolute Values of Heart Rate at Baseline (Day 1), Week 1, 2, 3, 4, and 6;Change From Baseline in Heart Rate at Week 1, 2, 3, 4, and 6;Absolute Electrocardiogram (ECG) Parameter Values at Baseline (Screening), Week 2, 4, and 6;Change From Baseline in ECG Parameters at Week 2, 4 and 6;Mean Maximum Plasma Concentration (Cmax) of GSK1278863 and GSK1278863 Metabolites;Mean Steady State Area Under the Curve (AUC) of GSK1278863 and GSK1278863 Metabolites